Table 2.
Presentation features associated with better BCVA.
| Factor | Number | Improved BCVA (%) | P value |
|---|---|---|---|
| Gender (n = 121) | |||
| Male | 103 | 98/103 (95.15) | 0.1781 |
| Female | 18 | 15/18 (83.3) | |
|
| |||
| Treatment period (n = 121) | |||
| <12 hrs | 111 | 109/111 (98.20) | 0.0000 |
| >12 hrs | 10 | 4/10 (40) | |
|
| |||
| PPV period (n = 121) | |||
| <24 hrs | 105 | 103/105 (98.10) | 0.0000 |
| >24 hrs | 16 | 10/16 (62.5) | |
|
| |||
| Laceration length (n = 121) | |||
| ⩽10 mm | 110 | 106/110 (96.36) | 0.0004 |
| >10 mm | 11 | 7/11 (63.63) | |
|
| |||
| Presenting VA (n = 121) | |||
| ⩾LP | 114 | 110/114 (96.49) | 0.0000 |
| <LP | 7 | 3/7 (42.86) | |
|
| |||
| IOFB | |||
| Yes | 53 | 48/53 (90.57) | 0.4627 |
| No | 68 | 65/68 (95.59) | |
|
| |||
| Retinal detachment | |||
| Yes | 37 | 33/37 (89.19) | 0.4028 |
| No | 84 | 80/84 (95.24) | |
|
| |||
| Corneal perforation | |||
| Yes | 85 | 82/85 (96.47) | 0.0898 |
| No | 36 | 31/36 (86.11) | |
|
| |||
| Scleral perforation | |||
| Yes | 36 | 31/36 (86.11) | 0.0898 |
| No | 85 | 82/85 (96.47) | |
|
| |||
| SO use | |||
| Yes | 98 | 91/98 (92.86) | 0.9846 |
| No | 23 | 22/23 (95.65) | |
|
| |||
| Lensectomy | |||
| Yes | 116 | 109/116 (93.97) | 0.7555 |
| No | 5 | 4/5 (80) | |
PPV: pars plana vitrectomy; IOFB: intraocular foreign body; SO: silicone oil.